SCHEMBL4110213

SCHEMBL4110213

CCN1CCC(NC(=O)c2ccc(Nc3ncc4c(n3)N(c3ccccc3)CC(C)(C)C(=O)N4C)c(OC)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 14/20 0.61
BRD4 O60885 10/20 0.59
DCLK1 O15075 3/20 0.59
MAPK7 Q13164 3/20 0.59
LRRK2 Q5S007 2/20 0.59
BRDT Q58F21 4/20 0.59
RAD52 P43351 1/20 0.58
PLK3 Q9H4B4 5/20 0.58
PRKD3 O94806 3/20 0.56
CLK2 P49760 3/20 0.56
PTK2 Q05397 3/20 0.56
CAMK2G Q13555 3/20 0.56
CAMK2D Q13557 3/20 0.56
PRKD2 Q9BZL6 3/20 0.56
CSNK1G1 Q9HCP0 3/20 0.56
CSNK1G3 Q9Y6M4 3/20 0.56
DAPK3 O43293 2/20 0.56
CHEK2 O96017 2/20 0.56
EGFR P00533 2/20 0.56
FES P07332 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107624 0.93 BRD4 (0.68) PLK1BRD4DCLK1MAPK7LRRK2
SCHEMBL1560854 0.93 PLK1 (0.67) PLK1BRD4DCLK1MAPK7LRRK2
SCHEMBL4104317 0.90 PLK1 (0.63) PLK1BRD4DCLK1MAPK7LRRK2
SCHEMBL3543178 0.89 PLK1 (0.64) PLK1BRD4DCLK1MAPK7LRRK2
SCHEMBL4115874 0.88 BRD4 (0.57) PLK1BRD4DCLK1MAPK7LRRK2
SCHEMBL4116815 0.88 PLK1 (0.69) PLK1BRD4DCLK1MAPK7LRRK2
SCHEMBL4109052 0.88 PLK1 (0.62) PLK1BRD4DCLK1MAPK7LRRK2
SCHEMBL4116844 0.87 PLK1 (0.58) PLK1BRD4DCLK1MAPK7LRRK2
SCHEMBL3540668 0.87 PLK1 (0.75) PLK1BRD4DCLK1MAPK7BRDT
SCHEMBL3994195 0.87 BRD4 (0.52) PLK1BRD4DCLK1MAPK7LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US claimed
WO-2009067547-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 WO claimed
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US disclosed
WO-2009067547-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK PLK1 1/4885BRD4 1323/4885DCLK1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.